← All indications
Immunotherapy
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
Subtype terms (3)
More specific conditions that are subtypes of Immunotherapy in the MeSH hierarchy.
- Immunization
52 drugs (31 approved, 21 experimental)
- Immunosuppression Therapy
63 drugs (47 approved, 16 experimental)
- Radioimmunotherapy
Drugs by status
Phase 4 trials (1)
Phase 3 trials (31)
- busulfan
- doxorubicin
- gemcitabine
- fluorouracil
- paclitaxel
- lapatinib
- megestrol
- dinutuximab
- nimotuzumab
- olanzapine
- vincristine
- ifosfamide
- carboplatin
- house dust mite allergen
- sorbitol
- cyclophosphamide
- bevacizumab
- visilizumab
- capecitabine
- dacarbazine
- vindesine
- oxaliplatin
- cisplatin
- tegafur
- thiotepa
- etoposide
- melphalan
- camrelizumab
- sintilimab
- toripalimab
- +1 more
Phase 2 trials (68)
- afatinib
- axitinib
- anlotinib
- atezolizumab
- petrolatum, white
- olaparib
- binimetinib
- blinatumomab
- irinotecan
- certolizumab pegol
- prednisone
- durvalumab
- encorafenib
- fruquintinib
- omalizumab
- nivolumab
- inotuzumab ozogamicin
- pembrolizumab
- lenvatinib
- leucovorin
- mpt0e028
- regorafenib
- palivizumab
- pemetrexed
- trastuzumab
- ipilimumab
- rc48-adc
- ruxolitinib
- s-1
- cetuximab
- +38 more
Phase 1 trials (16)
- autologous tumor infiltrating lymphocytes
- dc vaccine
- hetrombopag olamine
- aldesleukin
- autologous natural killer cells
- palbociclib
- peanut
- psca or muc1 targeting car-t cells
- rivaroxaban
- obi-833
- shr-1603
- adagloxad simolenin
- gpc3 and/or tgfβ targeting car-t cells
- caix car-t cell
- bcma car-nk cells
- [68ga] b7h3 affibody-bch